| 1 |
NCT03102918 |
Completed
Has Results |
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Self-report Instruments to Measure Cannabis Use
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03102918 |
2015P002013 |
CBD |
February 20, 2016 |
August 30, 2017 |
August 30, 2017 |
April 6, 2017 |
January 25, 2019 |
January 25, 2019 |
- McLean Hospital
Belmont, Massachusetts, United States
|
|
| 2 |
NCT03904849 |
Not yet recruiting |
Cannabidiol for Alcohol Use Disorder |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Medical University of South Carolina
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Average alcohol-induced sedation after medication ingestion
- Average subjective response to alcohol after medication ingestion
- Alcohol drinking in natural environment
|
16 |
All |
21 Years to 40 Years (Adult) |
NCT03904849 |
00086168 |
|
October 1, 2019 |
April 30, 2020 |
April 30, 2020 |
April 5, 2019 |
July 4, 2019 |
|
- Medical University of South Carolina
Charleston, South Carolina, United States
|
|
| 3 |
NCT03634189 |
Not yet recruiting |
Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C |
|
|
Interventional
|
Phase 1 |
- Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related serious adverse events and events of interest as assessed by MedDRA v5.1
|
20 |
All |
30 Years to 75 Years (Adult, Older Adult) |
NCT03634189 |
CAPITAL-AC |
CAPITAL-AC |
November 1, 2019 |
March 1, 2020 |
March 1, 2020 |
August 16, 2018 |
August 6, 2019 |
|
|
|
| 4 |
NCT03984565 |
Not yet recruiting |
Sublingual Cannabidiol for Chronic Pain |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Staci Gruber, Ph.D.
- Mclean Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in pain ratings on the Brief Pain Inventory (BPI)
- Change in ratings on the Pain Self-Efficacy Questionnaire (PSEQ)
- Change in pain ratings on the Numerical Rating Scale (NRS)
- (and 2 more...)
|
55 |
All |
21 Years and older (Adult, Older Adult) |
NCT03984565 |
2019P001480 |
|
September 1, 2019 |
August 31, 2021 |
August 31, 2021 |
June 13, 2019 |
June 13, 2019 |
|
|
|
| 5 |
NCT02548559 |
Recruiting |
Sublingual Cannabidiol for Anxiety |
|
|
Interventional
|
Phase 2 |
- Staci Gruber, Ph.D.
- Mclean Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change from Baseline in Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI)
- Change from Baseline in Anxiety Assessed by the Hamilton Anxiety Scale (HAM-A)
- Change from Baseline in Self-Reported Anxiety Assessed by the State-Trait Anxiety Inventory (STAI)
|
16 |
All |
18 Years and older (Adult, Older Adult) |
NCT02548559 |
2015P000959 |
|
August 14, 2018 |
August 2019 |
August 2019 |
September 14, 2015 |
August 15, 2018 |
|
- McLean Hospital Brain Imaging Center
Belmont, Massachusetts, United States
|
|
| 6 |
NCT03310593 |
Recruiting |
Cannabidiol as an Adjunctive Treatment for Bipolar Depression |
- Bipolar Disorder
- Bipolar Depression
- Bipolar Affective Disorder
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Hospital de Clinicas de Porto Alegre
- Federal University of Rio Grande do Sul
- University of Sao Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline Montgomery-Asberg Depression Rating Scale (MADRS) scores.
- Improvement in clinical global impression.
- Improvement in anxiety symptoms
- (and 11 more...)
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03310593 |
63811317300005327 |
CBDBD |
November 1, 2017 |
February 2021 |
April 2021 |
October 16, 2017 |
August 27, 2019 |
|
- Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande Do Sul, Brazil
|
|
| 7 |
NCT02332655 |
Active, not recruiting |
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome |
|
|
Interventional
|
Phase 1
Phase 2 |
- Anne Comi, MD
- GW Pharmaceuticals Ltd.
- Faneca 66 Foundation
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in seizure frequency
- Change in average seizure duration by seizure type
- Change in the number of episodes of status epilepticus, defined as convulsive seizure lasting longer than 10 minutes
- (and 2 more...)
|
10 |
All |
1 Month to 45 Years (Child, Adult) |
NCT02332655 |
IRB00029264 |
|
December 2014 |
June 2019 |
June 2019 |
January 7, 2015 |
January 8, 2019 |
|
- Kennedy Krieger Institute
Baltimore, Maryland, United States
|
|
| 8 |
NCT03248167 |
Not yet recruiting |
Cannabidiol as a Treatment for AUD Comorbid With PTSD |
- Alcohol Use Disorder
- Post Traumatic Stress Disorder
|
- Drug: Cannabidiol
- Drug: Placebos
|
Interventional
|
Phase 1
Phase 2 |
- NYU Langone Health
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of drinks per day
- Weekly percentage of heavy drinking days
- Weekly percentage of very heavy drinking days
- (and 8 more...)
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT03248167 |
17-00949 |
|
June 15, 2019 |
August 31, 2019 |
August 31, 2019 |
August 14, 2017 |
May 15, 2019 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 9 |
NCT03355300 |
Recruiting |
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures |
- Childhood Absence Epilepsy
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Number of Participants with Change from Baseline in Vital Signs at Visit 8
- Number of Participants with Change from Baseline in Physical Exam at Visit 8
- (and 3 more...)
|
30 |
All |
3 Years to 17 Years (Child) |
NCT03355300 |
INS011-17-113 |
|
February 20, 2018 |
November 2019 |
November 2019 |
November 28, 2017 |
June 11, 2019 |
|
- Nicklaus Children's Hospital
Miami, Florida, United States - Pediatric Epilepsy and Neurology Specialists
Tampa, Florida, United States - Clinical Integrative Research Center of Atlanta
Atlanta, Georgia, United States - (and 6 more...)
|
|
| 10 |
NCT03336242 |
Recruiting |
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures |
- Childhood Absence Epilepsy
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent Change from Baseline in Absence Seizure Counts Assessed by Video-electroencephalogram (EEG) at Visit 5
- Percent Change from Baseline in Time to Absence Seizure During Hyperventilation Testing on Video-EEG at Visit 5
- Percentage of Participants Seizure-Free at Visit 5
- (and 7 more...)
|
30 |
All |
3 Years to 17 Years (Child) |
NCT03336242 |
INS011-17-103 |
|
December 15, 2017 |
June 2019 |
June 2019 |
November 8, 2017 |
June 11, 2019 |
|
- University of California San Francisco/ Benioff Children's Hospital
San Francisco, California, United States - Nicklaus Children's Hospital
Miami, Florida, United States - Pediatric Epilepsy and Neurology Specialists
Tampa, Florida, United States - (and 9 more...)
|
|
| 11 |
NCT03164512 |
Active, not recruiting |
The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol |
- Cannabidiol Pharmacokinetics
|
- Drug: Oral or vaporized cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
|
19 |
All |
18 Years to 45 Years (Adult) |
NCT03164512 |
IRB00128331 |
|
June 1, 2018 |
August 29, 2019 |
October 30, 2019 |
May 23, 2017 |
September 2, 2019 |
|
- Johns Hopkins Behavioral Pharmacology Research Unit
Baltimore, Maryland, United States
|
|
| 12 |
NCT01596075 |
Unknown † |
Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation |
- Graft Versus Host Disease
|
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete resolution of acute GVHD
- Percentage of patients developing chronic GVHD
- percentage of patients developing > or = grade 3 toxicity
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT01596075 |
0388-11-RMC |
|
July 2012 |
July 2015 |
|
May 10, 2012 |
September 11, 2012 |
|
- Davidof Cancer Center, Beilinson hospital, Rabin medical center
Petach Tikva, Israel
|
|
| 13 |
NCT02660255 |
Approved for marketing |
Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy |
|
|
Expanded Access
|
|
- Christopher J. Kratochvil, M.D.
- GW Pharmaceuticals Ltd.
- University of Nebraska
|
Other / Industry |
|
|
|
All |
1 Year to 60 Years (Child, Adult) |
NCT02660255 |
719-15-FB |
CBD |
|
|
|
January 21, 2016 |
May 30, 2019 |
|
|
|
| 14 |
NCT02324673 |
Completed
Has Results |
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders |
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol
- Cmax for Cannabidiol and Metabolite 7-OH Cannabidiol
- Dose Normalized Cmax (Cmax/D) for Cannabidiol and Metabolite 7-OH Cannabidiol
- (and 28 more...)
|
61 |
All |
1 Year to 17 Years (Child) |
NCT02324673 |
INS011-14-029 |
|
April 13, 2015 |
May 9, 2016 |
May 9, 2016 |
December 24, 2014 |
June 23, 2017 |
June 23, 2017 |
- University of California San Francisco Medical Center
San Francisco, California, United States - Miami Children's Hospital
Miami, Florida, United States - Child Neurology Center - NW F
Pensacola, Florida, United States - (and 7 more...)
|
|
| 15 |
NCT03941288 |
Not yet recruiting |
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia |
|
- Drug: Cannabidiol
- Other: placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Primary endpoint gastric accommodation
- Primary Endpoint satiation
- Primary endpoint Gastric emptying
- (and 10 more...)
|
96 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03941288 |
19-002483 |
|
September 2019 |
June 2024 |
June 2024 |
May 7, 2019 |
August 13, 2019 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
|
| 16 |
NCT01385124 |
Unknown † |
Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation |
- Graft Versus Host Disease
|
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Overall percentage of patients with acute GVHD at day 100 post-transplant
- Percentage of patients with grade III/IV acute GVHD at day 100 post-transplant
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01385124 |
6276 |
|
September 2012 |
December 2015 |
|
June 29, 2011 |
June 19, 2015 |
|
- Davidoff Cancer Center, Beilin hospital, Rabin medical center
Petach Tikva, Israel
|
|
| 17 |
NCT03458416 |
Recruiting |
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome |
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) Associated with Cannabidiol Oral Solution
- Number of Participants with Change from Baseline in Vital Signs
- Number of Participants with Change from Baseline in Physical Exam
- (and 3 more...)
|
66 |
All |
8 Years to 17 Years (Child) |
NCT03458416 |
INS011-17-115 |
|
September 6, 2018 |
May 2020 |
May 2020 |
March 8, 2018 |
June 11, 2019 |
|
- Institute for Research and Innovation | MultiCare Health System
Tacoma, Washington, United States
|
|
| 18 |
NCT02818777 |
Completed
Has Results |
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease |
|
|
Interventional
|
Phase 2 |
- University of Colorado, Denver
- Colorado Department of Public Health and Environment
- GW Research Ltd
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Severity of Participants Reporting Study-related Adverse Events at Each Dose Level
- Number of Participants Had Changes in Orthostatic Blood Pressure
- Number of Participants Had Changes in Physical Exam
- (and 17 more...)
|
13 |
All |
40 Years to 80 Years (Adult, Older Adult) |
NCT02818777 |
15-0929 |
|
October 2016 |
November 2017 |
November 2017 |
June 30, 2016 |
February 19, 2019 |
February 19, 2019 |
- University of Colorado School of Medicine
Aurora, Colorado, United States
|
|
| 19 |
NCT04056442 |
Recruiting |
A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients |
- Steroid Dependent Crohn's Disease
|
- Drug: Cannabidiol , synthetic form
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Assessment of the safety and tolerability of up to 300 mg CBD/day measured by Adverse Events
- Efficacy will be mesursed by precentegae of reduction in dose of steroids without flares
- Percentage of patients without flares
- Percent of patients who did not demonstrate an increase in inflammatory activity
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT04056442 |
ST-SDCD-01 |
|
July 7, 2019 |
July 7, 2021 |
July 7, 2021 |
August 14, 2019 |
August 14, 2019 |
|
- Meir Medical Center
Kfar Saba, Israel
|
|
| 20 |
NCT03676049 |
Available |
Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use) |
|
|
Expanded Access
- Intermediate-size Population
|
|
- John
- University of Mississippi Medical Center
|
Other |
|
|
|
All |
5 Years to 19 Years (Child, Adult) |
NCT03676049 |
2017-0259 |
|
|
|
|
September 18, 2018 |
September 18, 2018 |
|
- University of Mississippi Medical Center
Jackson, Mississippi, United States
|
|
| 21 |
NCT02286986 |
Active, not recruiting |
Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy |
|
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Seizure Frequency
- Drug Plasma Levels of Cannabidiol
|
25 |
All |
2 Years to 25 Years (Child, Adult) |
NCT02286986 |
IND 70871 |
|
September 2014 |
January 2019 |
April 2019 |
November 10, 2014 |
July 19, 2018 |
|
- University of Utah School of Medicine
Salt Lake City, Utah, United States
|
|
| 22 |
NCT03891264 |
Recruiting |
Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain |
|
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Changes in brain PET signal
- Changes in pain outcomes as measured by self report on a 0-100 numerical pain rating scale.
|
20 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03891264 |
CBD_Pain_PET Trial |
CBD |
August 2019 |
June 2020 |
June 2020 |
March 27, 2019 |
August 14, 2019 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 23 |
NCT01037322 |
Completed |
Cannabidiol for Inflammatory Bowel Disease |
- Crohn's Disease
- Ulcerative Colitis
|
- Drug: cannabidiol
- Drug: placebo in drops
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- reduction of 70 points in CDAI
- change in quality of life during the study
- any adverse events during study period
|
20 |
All |
20 Years to 80 Years (Adult, Older Adult) |
NCT01037322 |
canabidiol1 |
|
January 2010 |
September 2012 |
September 2012 |
December 23, 2009 |
April 16, 2013 |
|
- Sapir Medical center Meir Hospital
Kefar Saba, Israel
|
|
| 24 |
NCT03471559 |
Recruiting |
Cannabidiol - an in Vivo Innovative Drug Delivery Study |
- Pharmacokinetics, Bioavailability
|
|
Interventional
|
Phase 1 |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Pharmacokinetic profile of single dose - area under the curve (AUC(0-t)), AUC(0-∞))
- Pharmacokinetic profile of single dose - residual area
- Pharmacokinetic profile of single dose - maximum concentration (Cmax)
- (and 13 more...)
|
24 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03471559 |
CBD-DDS |
|
December 10, 2018 |
May 31, 2019 |
August 31, 2019 |
March 20, 2018 |
December 13, 2018 |
|
- Department I of Pharmacology, University of Cologne
Cologne, Germany
|
|
| 25 |
NCT03014440 |
No longer available |
Study of Cannabidiol for Drug-Resistant Epilepsies |
|
|
Expanded Access
|
|
- Eric Marsh, MD
- University of Pittsburgh
- Geisinger Clinic
- Children's Hospital of Philadelphia
|
Other |
|
|
|
All |
1 Year to 20 Years (Child, Adult) |
NCT03014440 |
13-010562 |
|
|
|
|
January 9, 2017 |
April 4, 2017 |
|
|
|
| 26 |
NCT01311778 |
Completed |
Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse |
|
- Drug: Cannabidiol
- Drug: Fentanyl
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To determine the safety of cannabidiol oral administration prior to fentanyl IV administration.
- General cannabidiol pharmacokinetics
- Cortisol levels
- (and 11 more...)
|
18 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT01311778 |
R21DA027781 |
|
February 2010 |
October 2011 |
October 2011 |
March 10, 2011 |
March 22, 2013 |
|
- Mount Sinai Medical Center
New York, New York, United States
|
|
| 27 |
NCT03877991 |
Not yet recruiting |
Bioequivalence Assessment of Cannabidiol (CBD) Administrated in Oral Formulations |
|
- Drug: CBD-sesame oil capsule
- Drug: CBD-LNL capsule
- Drug: CBD powder form capsule
|
Interventional
|
Early Phase 1 |
- Hadassah Medical Organization
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- Pharmacokinetic parameters of CBD
- Exposure to the metabolites of the study drugs
|
12 |
Male |
18 Years to 45 Years (Adult) |
NCT03877991 |
0352-18-HMO-CTIL |
|
April 2019 |
August 2019 |
August 2019 |
March 18, 2019 |
March 22, 2019 |
|
- Hadassah Medical Organization
Jerusalem, Israel
|
|
| 28 |
NCT02551731 |
Terminated
Has Results |
Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms |
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Part A: Percentage of Participants Who Are Considered Complete Responders at Day 14
- Part B: Percentage of Participants Experiencing Adverse Events (AEs), Treatment-Emergent AEs (TEAEs), and Serious Adverse Events (SAEs)
- Part A: Percentage of Participants With Absence of Infantile Spasms at Day 14
- (and 11 more...)
|
9 |
All |
6 Months to 36 Months (Child) |
NCT02551731 |
INS011-15-054 |
|
January 27, 2016 |
September 6, 2016 |
September 6, 2016 |
September 16, 2015 |
September 19, 2018 |
September 19, 2018 |
- Mattel Children's Hospital at UCLA
Los Angeles, California, United States - University of California - San Francisco
San Francisco, California, United States - Miami Children's Hospital
Miami, Florida, United States - Beaumont Health System
Royal Oak, Michigan, United States
|
|
| 29 |
NCT03549819 |
Not yet recruiting |
Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study |
- Generalized Anxiety Disorder
- Social Anxiety Disorder
- Panic Disorder
- Agoraphobia
|
- Drug: Cannabidiol (CBD) Oil Capsules
- Drug: Sunflower Lecithin Oil in Capsule
|
Interventional
|
Phase 3 |
- McMaster University
- Tilray
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Anxiety Rating Scale (HAM-A)
- Clinical Global Impression - Severity (CGI-S)
- Clinical Global Impression - Improvement (CGI-I)
- (and 25 more...)
|
50 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03549819 |
CBD_ANX |
|
July 2019 |
August 2020 |
October 2020 |
June 8, 2018 |
June 18, 2019 |
|
- MacAnxiety Research Centre
Hamilton, Ontario, Canada
|
|
| 30 |
NCT03252756 |
Not yet recruiting |
Effects of Cannabidiol in Alcohol Use Disorder |
|
- Other: Placebo
- Drug: Phytocannabinoid cannabidiol (CBD)
|
Interventional
|
Phase 1
Phase 2 |
- NYU Langone Health
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Change in Time-line Follow-back (TLFB) assessment of alcohol consumption in Serum
- Change in Percent carbohydrate deficient transferrin (CDT) assessment of alcohol consumption in Serum
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03252756 |
17-01001 |
|
April 15, 2019 |
November 2019 |
January 2020 |
August 17, 2017 |
January 25, 2019 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 31 |
NCT02902081 |
Completed
Has Results |
Cannabidiol and Emotional Stimuli |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Not Applicable |
- University of Chicago
- INSYS Therapeutics Inc
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Positivity Ratings of Social Images
|
38 |
All |
18 Years to 35 Years (Adult) |
NCT02902081 |
IRB13-0215 |
CAS |
February 2013 |
March 2017 |
March 2017 |
September 15, 2016 |
August 28, 2019 |
August 28, 2019 |
- University of Chicago
Chicago, Illinois, United States
|
|
| 32 |
NCT02318563 |
Withdrawn |
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome |
|
- Drug: Cannabidiol Oral Solution
- Drug: Placebo Solution
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percent change in the frequency of tonic-clonic, clonic, and focal seizures with motor components
- Percent change from baseline in the severity of tonic-clonic, clonic, and focal seizures with motor components
- Percent change from baseline in the duration of tonic-clonic, clonic, and focal seizures with motor components
- (and 5 more...)
|
0 |
All |
1 Year to 30 Years (Child, Adult) |
NCT02318563 |
INS011-14-025 |
|
December 30, 2017 |
June 17, 2018 |
June 17, 2018 |
December 17, 2014 |
January 4, 2018 |
|
|
|
| 33 |
NCT02318537 |
Withdrawn |
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome |
|
- Drug: Cannabidiol Oral Solution
- Drug: Placebo Solution
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percent change from baseline in the frequency of motor seizures involving the trunk or extremities [tonic, atonic, generalized tonic-clonic (GTC), focal seizures with motor components (FSMC)]
- Percent change from baseline in severity of motor seizures involving the trunk or extremities (tonic, clonic, GTC, FSMC)
- Percent change from baseline in frequency of all seizure activity independent of seizure type
- (and 6 more...)
|
0 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02318537 |
INS011-14-024 |
|
December 30, 2017 |
June 30, 2018 |
June 30, 2018 |
December 17, 2014 |
January 4, 2018 |
|
|
|
| 34 |
NCT03787628 |
Not yet recruiting |
Cannabidiol as Adjunctive Treatment for Opioid Use Disorder |
|
- Drug: Cannabidiol Oral Solution
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Cue-induced opioid craving
- spontaneous opioid craving using the Penn Alcohol-Craving Scale adapted for opioid
- Spielberger State-Trait Anxiety Inventory
- (and 10 more...)
|
60 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03787628 |
18-001748 |
|
June 1, 2019 |
March 31, 2021 |
June 30, 2021 |
December 25, 2018 |
March 29, 2019 |
|
|
|
| 35 |
NCT02844933 |
Recruiting |
Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in the total score of the Hyperphagia Questionnaire for Clinical Trial (HQ-CT)
- Change from Baseline in Total Body-Weight
- Responder Rate from Baseline through Study Completion
- (and 4 more...)
|
66 |
All |
8 Years to 17 Years (Child) |
NCT02844933 |
INS011-16-085 |
|
June 6, 2018 |
June 2019 |
June 2019 |
July 26, 2016 |
June 11, 2019 |
|
- University of Arizona
Tucson, Arizona, United States - Rady Children's, UC San Diego
San Diego, California, United States - University of Iowa
Iowa City, Iowa, United States - (and 4 more...)
|
|
| 36 |
NCT02556008 |
No longer available |
Cannabidiol for Pediatric Epilepsy (Compassionate Use) |
- Refractory Childhood Epilepsy
|
|
Expanded Access
|
|
- University of California, Los Angeles
|
Other |
|
|
|
All |
1 Year to 17 Years (Child) |
NCT02556008 |
SH001 |
|
|
|
|
September 22, 2015 |
May 3, 2017 |
|
- University of California, Los Angeles
Los Angeles, California, United States
|
|
| 37 |
NCT02559167 |
Recruiting |
Cannabidiol and Cocaine Craving/Dependence |
- Substance Use Disorder
- Cocaine Dependence
- Withdrawal From Addictive Substance; Detoxification
|
|
Interventional
|
Phase 2 |
- Didier Jutras-Aswad
- Centre hospitalier de l'Université de Montréal (CHUM)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Drug-cue induced craving
- Number of days to relapse
- Stress-induced craving
- Cocaine use during the post-detoxification phase
|
110 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02559167 |
14.183 |
CBD |
February 2016 |
September 2019 |
December 2019 |
September 24, 2015 |
January 31, 2019 |
|
- Centre de recherche du Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
|
|
| 38 |
NCT03467620 |
Not yet recruiting |
Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease |
- Crohn Disease
- Inflammatory Bowel Diseases
- Cannabis
|
- Drug: Cannabidiol
- Drug: Placebo oral capsule
|
Interventional
|
Phase 2
Phase 3 |
- University of Illinois at Chicago
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- CDAI (Clinical Disease Activity Index) score
- Fecal calprotectin
- Morbidity
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03467620 |
CBD2018 |
|
July 2018 |
July 2019 |
July 2019 |
March 16, 2018 |
March 20, 2018 |
|
|
|
| 39 |
NCT03883360 |
Not yet recruiting |
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis |
- Schizophrenia Spectrum Disorders
- Cannabis Use
|
- Drug: Cannabidiol (CBD)
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of Maryland, Baltimore
- Sheppard Pratt Health System
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Brief Psychiatric Rating Scale (BPRS) total score
- Change in MATRICS Consensus Cognitive Battery (MCCB) composite score
- Change in Serum concentrations of THCCOOH
- (and 18 more...)
|
84 |
All |
18 Years to 35 Years (Adult) |
NCT03883360 |
HP-00082213 |
|
December 1, 2019 |
June 30, 2024 |
June 30, 2024 |
March 20, 2019 |
September 12, 2019 |
|
- Semel Institute for Neuroscience and Human Behavior
Los Angeles, California, United States - Sheppard Pratt Health System
Baltimore, Maryland, United States - Maryland Psychiatric Research Center
Catonsville, Maryland, United States
|
|
| 40 |
NCT03196934 |
Available |
Expanded Use of Cannabidiol Oral Solution |
|
- Drug: Cannabidiol oral solution
|
Expanded Access
- Intermediate-size Population
|
|
- Steven Phillips
- MultiCare Health System Research Institute
|
Other |
|
|
|
All |
1 Year to 18 Years (Child, Adult) |
NCT03196934 |
MulticareHSRI |
|
|
|
|
June 23, 2017 |
June 23, 2017 |
|
|
|
| 41 |
NCT03518801 |
Recruiting |
Cannabidiol and Prolonged Exposure |
|
- Behavioral: Prolonged Exposure
- Drug: Cannabidiol
- Drug: placebo
|
Interventional
|
Phase 2 |
- VA Office of Research and Development
- University of California, San Diego
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinician-Administered PTSD Scale DSM 5 (CAPS-5)
- PTSD Checklist (PCL-5)
|
136 |
All |
18 Years and older (Adult, Older Adult) |
NCT03518801 |
MHBB-001-17F |
CBD-PE |
March 1, 2019 |
September 30, 2023 |
September 30, 2023 |
May 8, 2018 |
August 7, 2019 |
|
- VA San Diego Healthcare System, San Diego, CA
San Diego, California, United States
|
|
| 42 |
NCT01605539 |
Completed
Has Results |
Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans |
|
- Drug: Cannabidiol 400
- Drug: Cannabidiol 800
- Drug: Control
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC)
- Changes in Out-of-Clinic Craving (From Pre-Dose to Approximately 6 Hours Post-Dose for Test Visits I and II; and From Pre-Dose Test Visit I to Pre-Cue Test Visit IV) - Via the Heroin Craving Questionnaire (HCQ)
- Vital Signs - Blood Pressure
- (and 6 more...)
|
10 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT01605539 |
R21 DA027781(2) |
|
May 2012 |
October 2013 |
October 2013 |
May 25, 2012 |
November 28, 2016 |
November 28, 2016 |
- Mount Sinai Medical Center
New York, New York, United States
|
|
| 43 |
NCT03421496 |
Active, not recruiting |
A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms |
|
- Drug: Cannabidiol Oral Solution
- Drug: Placebo
- Drug: Vigabatrin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants Considered Complete Responders
- Percentage of Participants with Resolution of Infantile Spasms
- Percentage of Participants with Resolution of Hypsarrhythmia
- (and 3 more...)
|
190 |
All |
1 Month to 24 Months (Child) |
NCT03421496 |
INS011-16-082 |
|
September 5, 2018 |
December 2019 |
December 2019 |
February 5, 2018 |
June 11, 2019 |
|
- Nicklaus Children's Hospital
Miami, Florida, United States - Beaumont Children's Hospital
Royal Oak, Michigan, United States - Akron Children's Hospital
Akron, Ohio, United States - (and 2 more...)
|
|
| 44 |
NCT02783092 |
Recruiting |
A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Antonio Waldo Zuardi
- Prati Donaduzzi & Cia Ltda
- University of Sao Paulo
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Frequency of epileptic seizures
|
126 |
All |
2 Years to 18 Years (Child, Adult) |
NCT02783092 |
CBD-PRATI-USP_01 |
|
November 9, 2018 |
August 2020 |
December 2020 |
May 26, 2016 |
November 27, 2018 |
|
- Unidade de Pesquisa Clínica HCRP-USP
Ribeirao Preto, Sao Paulo, Brazil
|
|
| 45 |
NCT02318602 |
Completed
Has Results |
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder |
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Adverse Events
- Percentage of Participants With Serious Adverse Events
- Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Values
- (and 5 more...)
|
52 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02318602 |
INS011-14-030 |
|
January 8, 2016 |
June 22, 2017 |
June 22, 2017 |
December 17, 2014 |
July 25, 2018 |
July 25, 2018 |
- University of California San Francisco Medical Center
San Francisco, California, United States - Miami Children's Hospital
Miami, Florida, United States - Child Neurology Center - NW F
Pensacola, Florida, United States - (and 8 more...)
|
|
| 46 |
NCT01844687 |
Completed
Has Results |
Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana |
|
|
Interventional
|
Phase 2 |
- Steve Sparenborg
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Mood Scale - Subscale 'Feeling High'
|
50 |
All |
18 Years to 50 Years (Adult) |
NCT01844687 |
Study Number CBD-001 |
|
May 2013 |
October 2014 |
October 2014 |
May 1, 2013 |
April 25, 2017 |
April 25, 2017 |
- University of Kentucky, Straus Behavioral Research Bldg., 515 Oldham Ct.
Lexington, Kentucky, United States - Marijuana Outpatient Lab 1051 Riverside Dr. Unit #120
New York, New York, United States - Center for Drug and Alcohol Programs, Room 459 North, 67 President St.
Charleston, South Carolina, United States
|
|
| 47 |
NCT03215940 |
Recruiting |
Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC) |
|
- Drug: Delta-9-Tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: Placebos
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Brain Changes
- Improvement in pain relief
|
75 |
All |
18 Years to 50 Years (Adult) |
NCT03215940 |
IRB_00103451 |
|
February 1, 2018 |
October 2019 |
December 2019 |
July 12, 2017 |
January 9, 2019 |
|
- University Of Utah
Salt Lake City, Utah, United States
|
|
| 48 |
NCT02088060 |
Active, not recruiting |
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients |
|
- Drug: Cannabidiol
- Drug: Olanzapine
- Drug: Placebo Cannabidiol
- Drug: Placebo Olanzapine
|
Interventional
|
Phase 2 |
- Central Institute of Mental Health, Mannheim
- Martin-Luther-Universität Halle-Wittenberg
- Heidelberg University
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Positive and Negative Syndrome Scale (PANSS) total score
- Changes in the PANSS subscores and clusters
- Changes in the Clinical Global Impression score
- (and 10 more...)
|
150 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02088060 |
CBD-FEP
2012-004335-23 |
|
March 2014 |
August 2021 |
December 2021 |
March 14, 2014 |
August 14, 2019 |
|
- Psychiatric Centre Glostrup
Glostrup, Denmark - Department of General Psychiatry, Heidelberg University
Heidelberg, BW, Germany - Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health
Mannheim, BW, Germany - (and 3 more...)
|
|
| 49 |
NCT02461706 |
No longer available |
Treatment of Drug Resistant Epilepsy |
|
- Drug: cannabidiol
- Other: Blood Test
|
Expanded Access
|
|
- University of Florida
- James and Esther King Biomedical Research Program
|
Other |
|
|
|
All |
2 Years to 16 Years (Child) |
NCT02461706 |
IRB201401013
FLGV |
Cannabidiol |
|
|
|
June 3, 2015 |
January 21, 2019 |
|
- University of Flordia CRC
Gainesville, Florida, United States - Nicklaus Children's Hospital, Miami Children's Health System
Miami, Florida, United States
|
|
| 50 |
NCT02392780 |
Unknown † |
Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease |
- Acute-graft-versus-host Disease
|
- Drug: Cannabidiol
- Drug: Methylprednisolone
- Drug: Calcineurin inhibitor
|
Interventional
|
Phase 2 |
- moshe yeshurun
- Rabin Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients with complete remission of acute GVHD
- Proportion of patients with partial remission of acute GVHD
- Proportion of patients with chronic GVHD
- (and 2 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT02392780 |
0009-15-RMC |
|
April 2015 |
April 2018 |
|
March 19, 2015 |
March 19, 2015 |
|
- Davidof Cancer Center, Beilinson hospital, Rabin medical center
Petach Tikva, Israel
|
|
| 51 |
NCT02815540 |
Terminated |
The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy |
- Lennox-Gastaut Syndrome
- Dravet Syndrome
|
- Procedure: 12-Lead ECG
- Drug: Cannabidiol
|
Interventional
|
Phase 1
Phase 2 |
- Gillette Children's Specialty Healthcare
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Holter SDNN parameter change
- Seizure frequency
- Dysautonomia signs and symptoms
|
2 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02815540 |
CBD-001 |
CBD1 |
February 16, 2017 |
December 1, 2018 |
December 1, 2018 |
June 28, 2016 |
March 4, 2019 |
|
- Gillette Children's Specialty Healthcare
Saint Paul, Minnesota, United States
|
|
| 52 |
NCT03848832 |
Recruiting |
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome |
|
- Drug: GWP42003-P
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Rett Syndrome Behaviour Questionnaire (RSBQ)
- Clinical Global Impressions - Improvement (CGI-I)
- Rett Syndrome Behavior Questionnaire subscales
- (and 3 more...)
|
252 |
Female |
2 Years to 18 Years (Child, Adult) |
NCT03848832 |
GWND18064
2018-003370-27 |
ARCH |
July 29, 2019 |
August 2021 |
September 2021 |
February 21, 2019 |
August 20, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Rady Children's Hospital
San Diego, California, United States - Children's Hospital Colorado
Aurora, Colorado, United States - (and 14 more...)
|
|
| 53 |
NCT02953548 |
Active, not recruiting |
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants who experienced a treatment-emergent adverse event.
- Number of participants with a potentially clinically significant change in clinical laboratory tests.
- Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).
- (and 4 more...)
|
10 |
All |
1 Month to 24 Months (Child) |
NCT02953548 |
GWEP15100 Pilot Phase
2015-004904-50 |
|
March 16, 2017 |
October 2018 |
October 2018 |
November 2, 2016 |
July 17, 2018 |
|
- Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States - Nationwide Children's Hospital
Columbus, Ohio, United States - Le Bonheur Children's Hospital
Memphis, Tennessee, United States - (and 3 more...)
|
|
| 54 |
NCT02954887 |
Active, not recruiting |
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants who experienced a treatment-emergent adverse event.
- Number of participants with a potentially clinically significant change in clinical laboratory tests.
- Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).
- (and 11 more...)
|
202 |
All |
1 Month to 24 Months (Child) |
NCT02954887 |
GWEP15100 Open-label Extension
2015-004904-50 |
|
May 9, 2017 |
December 2018 |
December 2018 |
November 4, 2016 |
July 16, 2018 |
|
- Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States - Nationwide Children's Hospital
Columbus, Ohio, United States - Le Bonheur Children's Hospital
Memphis, Tennessee, United States - (and 3 more...)
|
|
| 55 |
NCT02044809 |
Completed |
Cannabidiol: a Novel Intervention for Cannabis Use Problems? |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University College, London
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Urinary 11-nor-9-Carboxy-delta-9-tetrahydrocannabinol:creatinine (THC-COOH:creatinine)
- Number of days abstinent from cannabis
- Diagnostic and Statistical Manual- 5 (DSM-5) criteria for moderate cannabis dependence
- (and 2 more...)
|
82 |
All |
16 Years to 60 Years (Child, Adult) |
NCT02044809 |
12/0278 |
|
March 2014 |
February 9, 2017 |
June 5, 2017 |
January 24, 2014 |
October 24, 2018 |
|
- Clinical Psychopharmacology Unit
London, United Kingdom
|
|
| 56 |
NCT03582137 |
Recruiting |
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease |
|
- Drug: Cannabidiol
- Other: Placebo
|
Interventional
|
Phase 2 |
- University of Colorado, Denver
- Colorado Department of Public Health and Environment
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Movement Disorders Society-Unified Parkinson's disease rating scale (MDS-UPDRS) Part III (motor examination) scores
- Change in Frequency of study-related adverse events
- Change in Liver function monitoring --Liver function test
- (and 54 more...)
|
75 |
All |
40 Years to 85 Years (Adult, Older Adult) |
NCT03582137 |
17-2318 |
|
September 17, 2018 |
December 2019 |
June 2020 |
July 10, 2018 |
January 21, 2019 |
|
- University of Colorado hospital
Aurora, Colorado, United States
|
|
| 57 |
NCT02910297 |
Withdrawn |
The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy |
- Dravet Syndrome
- Lennox Gastaut Syndrome
|
|
Observational
|
|
- Gillette Children's Specialty Healthcare
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- Reduction in seizures
- Cannabidiol concentration
|
0 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02910297 |
CBD-PK-1 |
|
September 2016 |
December 31, 2017 |
December 31, 2017 |
September 22, 2016 |
February 26, 2019 |
|
|
|
| 58 |
NCT02224703 |
Completed
Has Results |
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome |
|
- Drug: GWP42003-P
- Drug: Placebo Control
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change In Convulsive Seizures During The Treatment Period Compared To Baseline
- Change In Total Seizures During The Treatment Period Compared To Baseline
- Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
- Caregiver Global Impression Of Change (CGIC) At The Last Visit
|
199 |
All |
2 Years to 18 Years (Child, Adult) |
NCT02224703 |
GWEP1424
2014-002939-34 |
|
April 13, 2015 |
April 9, 2018 |
April 9, 2018 |
August 25, 2014 |
August 1, 2019 |
August 1, 2019 |
- Birmingham, Alabama, United States
- Little Rock, Arkansas, United States
- Los Angeles, California, United States
- (and 35 more...)
|
|
| 59 |
NCT02051387 |
Completed |
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study |
|
- Drug: Cannabidiol CR
- Drug: Cannabidiol
- Drug: Amisulpride
- (and 4 more...)
|
Interventional
|
Phase 1 |
- Central Institute of Mental Health, Mannheim
- University of Cologne
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Plasma levels of cannabidiol
- Area Under Curve (AUC)
- serum antipsychotic concentration
|
74 |
All |
18 Years to 45 Years (Adult) |
NCT02051387 |
CBD-IS
2008-008245-38 |
CBD-IS |
January 2013 |
August 2017 |
August 2017 |
January 31, 2014 |
March 8, 2018 |
|
- Central Institute of Mental Health
Mannheim, BW, Germany - Dept. of Pharmacology, University of Cologne
Cologne, NRW, Germany
|
|
| 60 |
NCT02083874 |
Unknown † |
Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study |
|
|
Interventional
|
Phase 2 |
- The University of New South Wales
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Severity of cannabis withdrawal
- Safety of CBD for cannabis withdrawal
- Treatment retention
|
5 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02083874 |
NCPIC2014001 |
|
March 2014 |
September 2014 |
December 2014 |
March 11, 2014 |
March 11, 2014 |
|
|
|
| 61 |
NCT02478424 |
Unknown † |
Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease |
|
- Drug: Cannabidiol
- Drug: cyclosporine
- Drug: Methotrexate
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Incidence of grade 2-4 and grade 3-4 acute GVHD by day 100
- grade 3-4 adverse effects attributed to CBD consumption
- Incidence of overall chronic GVHD and moderate to severe chronic GVHD by 12 months
- (and 6 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT02478424 |
RMC-0208-14 |
|
July 2015 |
December 2016 |
June 2017 |
June 23, 2015 |
June 23, 2015 |
|
|
|
| 62 |
NCT03900923 |
Recruiting |
Cannabidiol for ASD Open Trial |
- ASD
- Autism Spectrum Disorder
|
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Global Impression Scale -Improvement (CGI-I)
- Brief Observation of Social Communication - Change (BOSCC)
- Repetitive Behavior Scale-Revised (RBS-R)
- (and 9 more...)
|
30 |
All |
7 Years to 17 Years (Child) |
NCT03900923 |
18-00250 |
|
March 12, 2019 |
January 31, 2021 |
January 31, 2021 |
April 3, 2019 |
June 4, 2019 |
|
- NYU Langone Health
New York, New York, United States
|
|
| 63 |
NCT02926859 |
Recruiting |
Enhancing Recovery in Early Schizophrenia |
|
- Drug: Cannabidiol as add-on
- Drug: Placebo as add-on
|
Interventional
|
Phase 2 |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- All-cause discontinuation
- Improvement in Psychopathology assessed by PANSS
- Improvement in Psychopathology assessed by CGI
- (and 16 more...)
|
180 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02926859 |
CBD-ESPRIT |
|
April 8, 2017 |
March 2020 |
March 2020 |
October 6, 2016 |
May 10, 2019 |
|
- Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health
Mannheim, BW, Germany - Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich
Munich, BY, Germany - Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte
Berlin, B, Germany - (and 2 more...)
|
|
| 64 |
NCT00309413 |
Completed |
A Clinical Trial on the Antipsychotic Properties of Cannabidiol |
- Schizophrenia
- Psychotic Disorders
|
- Drug: Placebo/Cannabidiol
- Drug: Cannabidiol/Placebo
|
Interventional
|
Phase 2 |
- University of Cologne
- Stanley Medical Research Institute
- Coordinating Centre for Clinical Trials Cologne
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- BPRS
- PANSS, EPS, Prolactin, ECG etc.
|
29 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00309413 |
CBD-PT 04-153 |
|
March 2006 |
March 2008 |
July 2008 |
March 31, 2006 |
July 25, 2008 |
|
- University of Cologne, Dept. of Psychiatry and Psychotherapy
Cologne, NRW, Germany
|
|
| 65 |
NCT04039919 |
Recruiting |
A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol |
|
- Drug: Padsevonil
- Drug: Placebo (PSL)
|
Interventional
|
Phase 1 |
- UCB Biopharma S.P.R.L.
- UCB Pharma
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Percentage of smooth pursuit eye movements during Part A during Period 1 (Day 1)
- Percentage of smooth pursuit eye movements during Part A during Period 2 (Day 1)
- Percentage of smooth pursuit eye movements during Part A during Period 4 (Day 5)
- (and 27 more...)
|
44 |
All |
18 Years to 55 Years (Adult) |
NCT04039919 |
UP0071
2019-000703-32 |
|
July 17, 2019 |
March 2020 |
March 2020 |
July 31, 2019 |
August 27, 2019 |
|
- Up0071 001
Leiden, Netherlands
|
|
| 66 |
NCT02504151 |
Active, not recruiting |
Cannabidiol Treatment in Patients With Early Psychosis |
- Schizophrenia
- Schizoaffective Disorder
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Positive and Negative Sydrome Scale
- Clinical Global Impression of Severity scale
- Patient Assessment of Own Functioning Inventory
- Quality of Life Scale
|
72 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02504151 |
1412015000 |
CBD |
August 2015 |
August 2019 |
December 2019 |
July 21, 2015 |
October 15, 2018 |
|
- Connecticut Mental Health Center
New Haven, Connecticut, United States - VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 67 |
NCT03985995 |
Not yet recruiting |
Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults |
- Pain Sensation
- Hyperalgesia
- Allodynia
|
- Drug: CBD 800 mg p.o
- Drug: Placebo p.o
|
Interventional
|
Not Applicable |
- University Hospital, Basel, Switzerland
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Change in pain (numeric rating scale (NRS): 0 = no pain and 10 = maximum tolerable pain)
- Change in area of hyperalgesia (cm)
- Change in area of allodynia (cm)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03985995 |
2019-00839; qu18Ruppen2 |
CANAB I |
November 2019 |
January 2020 |
January 2020 |
June 14, 2019 |
August 14, 2019 |
|
- Department of Anaesthesiology, University Hospital of Basel (USB)
Basel, Switzerland
|
|
| 68 |
NCT02224690 |
Completed
Has Results |
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults |
- Epilepsy
- Lennox-Gastaut Syndrome
|
- Drug: GWP42003-P 20 mg/kg/day Dose
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
- Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period
- Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
- Subject/Caregiver Global Impression Of Change Assessment (S/CGIC)
|
171 |
All |
2 Years to 55 Years (Child, Adult) |
NCT02224690 |
GWEP1423
2014-002941-23 |
GWPCARE4 |
April 28, 2015 |
March 18, 2016 |
March 18, 2016 |
August 25, 2014 |
July 27, 2018 |
July 27, 2018 |
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- (and 21 more...)
|
|
| 69 |
NCT02224573 |
Active, not recruiting |
GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes |
- Epilepsy
- Dravet Syndrome
- Lennox-Gastaut Syndrome
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The incidence of adverse events and other assessments as measure of subject safety.
- Mean change in quality of life, relative to the pre-randomization baseline of the Core Study, if assessed during the Core Study.
- Changes in the Caregiver Global Impression of Change (CGIC) or Subject Global Impression of Change score, relative to the pre-randomization baseline of the Core Study, if assessed during the Core Study.
- (and 8 more...)
|
681 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT02224573 |
GWEP1415
2014-001834-27 |
|
June 2015 |
June 2020 |
June 2020 |
August 25, 2014 |
June 7, 2019 |
|
|
|
| 70 |
NCT04059978 |
Not yet recruiting |
Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults |
- Acute Nociceptive Pain
- Hyperalgesia
- Allodynia
- Opioid-induced Hyperalgesia
|
- Drug: CBD
- Drug: Placebo
- Drug: Remifentanil
|
Interventional
|
Not Applicable |
- University Hospital, Basel, Switzerland
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Change in hyperalgesia measured by the area under the curve (AUCHyper)
- Change in pain response (NRS) measured by the area under the curve (AUCNRS)
- Change in allodynia measured by the area under the curve (AUCAllo)
|
23 |
All |
18 Years and older (Adult, Older Adult) |
NCT04059978 |
2019-01217; qu18Ruppen3 |
CANAB II |
January 2020 |
May 2020 |
May 2020 |
August 16, 2019 |
August 16, 2019 |
|
- Department of Anaesthesiology, University Hospital of Basel (USB)
Basel, Switzerland
|
|
| 71 |
NCT02447198 |
Completed |
Cannabidiol (CBD) and Pediatric Epilepsy |
|
|
Observational
|
|
- University of Colorado, Denver
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Describe the plasma pharmacokinetics of Cannabidiol (CBD), other antiepileptic drugs, Tetrahydrocannibinol (THC), and their respective metabolites in pediatric patients with epilepsy.
- Demographic Data
- Medication History
- (and 2 more...)
|
42 |
All |
31 Days to 17 Years (Child) |
NCT02447198 |
15-0216
UL1TR001082 |
|
November 2, 2015 |
September 11, 2018 |
September 11, 2018 |
May 18, 2015 |
October 30, 2018 |
|
- Children's Hospital Colorado
Aurora, Colorado, United States
|
|
| 72 |
NCT04044729 |
Not yet recruiting |
Mechanisms of CBD for Chronic Pain |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Neurochemical Brain Changes
- Pain Improvement
|
52 |
All |
18 Years to 50 Years (Adult) |
NCT04044729 |
IRB_00124865 |
|
January 1, 2020 |
December 30, 2020 |
December 30, 2021 |
August 5, 2019 |
August 5, 2019 |
|
|
|
| 73 |
NCT04030442 |
Recruiting |
Cannabidiol, Morphine, Pain |
|
- Drug: Immediate-release Oral Morphine Sulfate Tablets
- Other: Thermal and Pressure Nociceptive Sensitivity
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- CHANGE. PAIN THRESHOLD AND TOLERANCE Pain responses to a range of heat, cold and mechanical pressure stimuli
- SAFETY Systolic blood pressure (physiological effects)
- SAFETY Diastolic blood pressure (physiological effects)
- (and 5 more...)
|
40 |
All |
18 Years to 55 Years (Adult) |
NCT04030442 |
CMP |
CMP |
May 1, 2019 |
May 1, 2021 |
December 1, 2021 |
July 24, 2019 |
July 24, 2019 |
|
- Tolan Park Medical Building
Detroit, Michigan, United States
|
|
| 74 |
NCT03024827 |
Recruiting |
Cannabidiol in Children With Refractory Epileptic Encephalopathy |
|
|
Interventional
|
Phase 1 |
- University of Saskatchewan
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Heart Rate
- Blood Pressure
- Weight
- (and 19 more...)
|
28 |
All |
1 Year to 10 Years (Child) |
NCT03024827 |
CARE-E-01 |
CARE-E |
April 26, 2017 |
July 2019 |
December 2019 |
January 19, 2017 |
October 15, 2018 |
|
- University of British Columbia
Vancouver, British Columbia, Canada - University of Manitoba
Winnipeg, Manitoba, Canada - Universite de Montreal
Montreal, Quebec, Canada - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
|
|
| 75 |
NCT03295903 |
Unknown † |
Cannabinoid Supplementation on Vascular and Cognitive Function |
|
- Dietary Supplement: Cannabidiol supplement
|
Interventional
|
Early Phase 1 |
- University of British Columbia
- Lexaria Bioscoence Corp
- Mitacs
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Circulating cannabidiol and nitric oxide markers
- Vascular function
- Height
- (and 11 more...)
|
24 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03295903 |
H17-01957 |
|
October 2017 |
July 2019 |
August 2019 |
September 28, 2017 |
September 28, 2017 |
|
- University of British Columbia
Kelowna, Ontario, Canada
|
|
| 76 |
NCT02564952 |
Completed
Has Results |
An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol |
|
- Drug: GWP42003-P
- Drug: Clobazam
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number Of Participants Who Experienced Severe OLE-Emergent AEs
|
18 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02564952 |
GWEP1428 Open-Label Extension
2014-002942-33 |
|
March 11, 2016 |
June 7, 2017 |
June 7, 2017 |
October 1, 2015 |
September 11, 2018 |
September 11, 2018 |
- Barcelona, Spain
- Barcelona, Spain
- Birmingham, United Kingdom
- (and 3 more...)
|
|
| 77 |
NCT00588731 |
Completed
Has Results |
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia |
- Schizophrenia
- Schizoaffective Disorder
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Yale University
- Stanley Medical Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Verbal Short Term Memory
- Overall Cognition as Measured on the MATRICS Battery
|
41 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00588731 |
0710003164
07TGS-1082 |
|
February 2009 |
December 2013 |
December 2013 |
January 9, 2008 |
June 8, 2017 |
June 8, 2017 |
- Yale University
New Haven, Connecticut, United States
|
|
| 78 |
NCT02544750 |
Enrolling by invitation |
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) |
- Tuberous Sclerosis Complex
- Seizures
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events
- Change in seizure frequency
- Number of treatment responders
- (and 18 more...)
|
210 |
All |
1 Year to 65 Years (Child, Adult, Older Adult) |
NCT02544750 |
GWEP1521 Open-Label Extension
2015-002154-12 |
|
August 2016 |
February 2022 |
February 2022 |
September 9, 2015 |
October 1, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 79 |
NCT02544763 |
Completed |
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) |
- Tuberous Sclerosis Complex
- Seizures
|
- Drug: GWP42003-P
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in seizure frequency
- Number of treatment responders
- Number of participants with worsening, no change, or improvements in seizure frequency
- (and 18 more...)
|
224 |
All |
1 Year to 65 Years (Child, Adult, Older Adult) |
NCT02544763 |
GWEP1521 Blinded Phase
2015-002154-12 |
|
April 6, 2016 |
January 22, 2019 |
February 26, 2019 |
September 9, 2015 |
June 7, 2019 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 80 |
NCT01893424 |
Completed |
Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol) |
|
- Drug: Sativex buccal spray
- Drug: CBD-THC-Piperine-PNL capsule
|
Interventional
|
Phase 1 |
- Hadassah Medical Organization
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Pharmacokinetic parameters of THC and CBD
- exposure to the metabolites of the study drugs
|
12 |
Male |
18 Years to 45 Years (Adult) |
NCT01893424 |
0658-12-HMO-CTIL |
|
August 2013 |
January 2014 |
January 2015 |
July 9, 2013 |
March 24, 2016 |
|
- Hadassah medical organization
Jerusalem, Israel
|
|
| 81 |
NCT02291536 |
Completed |
Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD) |
|
- Drug: tetrahydrocannabinol
- Drug: cannabidiol
- Other: placebo
|
Interventional
|
Not Applicable |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Correctly identified emotional pictures during the attentional blink period
- Reaction time to correctly identified emotional pictures during the attentional blink period
|
20 |
Male |
18 Years to 65 Years (Adult, Older Adult) |
NCT02291536 |
AB_THC_CBD |
AB_THC_CBD |
February 2014 |
December 2014 |
December 2014 |
November 14, 2014 |
January 16, 2015 |
|
- Central Institute of Mental Health
Mannheim, Germany
|
|
| 82 |
NCT00628290 |
Completed |
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis |
|
- Drug: Cannabidiol
- Drug: Amisulpride
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in BPRS total value.
- Change in PANSS scores.
- EPS
- (and 2 more...)
|
42 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00628290 |
CBD-CT1
SMRI Grant ID: 00-093 |
CBD-CT1 |
October 2002 |
November 2004 |
March 2008 |
March 5, 2008 |
March 18, 2008 |
|
- University of Cologne, Dept. of Psychiatry and Psychotherapy
Cologne, NRW, Germany
|
|
| 83 |
NCT02777502 |
Completed |
Effects of Cannabidiol on Marijuana-seeking in Humans |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Marijuana Craving Visual Analog Scale (VAS) (Self-report measure)
- Marijuana Craving Questionnaire (Self-report measure)
- Marijuana Rating Form (Self-report measure)
- (and 10 more...)
|
30 |
All |
21 Years to 45 Years (Adult) |
NCT02777502 |
CBD-1 |
|
January 1, 2016 |
January 2019 |
January 2019 |
May 19, 2016 |
March 25, 2019 |
|
- Tolan Park Medical Building
Detroit, Michigan, United States
|
|
| 84 |
NCT02987114 |
Completed |
A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy |
|
|
Interventional
|
Phase 2 |
- PhytoTech Therapeutics, Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of study treatment related adverse events (AEs)
- Percent change in mean countable monthly seizure frequency
- Incidence of all adverse events (AEs)
- (and 2 more...)
|
16 |
All |
2 Years to 15 Years (Child) |
NCT02987114 |
CS-100 |
|
February 13, 2017 |
June 28, 2018 |
June 28, 2018 |
December 8, 2016 |
September 6, 2018 |
|
- Pediatric Epilepsy department- Souraskey Medical center
Tel Aviv, Israel
|
|
| 85 |
NCT02565108 |
Completed
Has Results |
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol |
|
- Drug: GWP42003-P 20 mg/kg/Day Dose
- Drug: Placebo
- Drug: Clobazam
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pharmacokinetics (PK): Maximum Measured Plasma Concentration (Cmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33
- PK: Time To The Maximum Plasma Concentration (Tmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33
- PK: Area Under The Plasma Concentration‑Time Curve Over A Dosing Interval, Where Tau Is The Dosing Interval (AUCtau) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33
- (and 3 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02565108 |
GWEP1428 Blinded Phase
2014-002942-33 |
|
January 20, 2016 |
July 21, 2016 |
July 21, 2016 |
October 1, 2015 |
August 23, 2018 |
August 23, 2018 |
- Barcelona, Spain
- Barcelona, Spain
- Birmingham, United Kingdom
- (and 3 more...)
|
|
| 86 |
NCT01180374 |
Active, not recruiting |
The Effects of Cannabidiol and ∆-9-THC in Humans |
|
- Drug: Cannabidiol
- Drug: Delta-9-THC
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
|
75 |
All |
18 Years to 55 Years (Adult) |
NCT01180374 |
1001006240 |
|
June 2010 |
July 2019 |
July 2019 |
August 12, 2010 |
July 10, 2019 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 87 |
NCT02091375 |
Completed
Has Results |
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) |
|
- Drug: GWP42003-P 20 mg/kg/day Dose
- Drug: Placebo control
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period
- Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
- Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
- (and 9 more...)
|
120 |
All |
2 Years to 18 Years (Child, Adult) |
NCT02091375 |
GWEP1332 Part B
2014-002941-23 |
|
March 30, 2015 |
November 26, 2015 |
November 26, 2015 |
March 19, 2014 |
August 27, 2018 |
July 20, 2018 |
- Miami, Florida, United States
- Orlando, Florida, United States
- Atlanta, Georgia, United States
- (and 19 more...)
|
|
| 88 |
NCT03840512 |
Recruiting |
An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD) |
|
|
Interventional
|
Phase 2 |
- Kalytera Therapeutics Israel, Ltd.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Adverse Events (AEs) and serious adverse events (SAEs) Reporting
- Cumulative incidence of aGVHD at day 100 post-transplant
- Pharmacokinetic parameters of Cannabidiol (CBD) - Cmax
- (and 7 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03840512 |
KAL05 |
|
June 12, 2018 |
October 15, 2019 |
November 15, 2019 |
February 15, 2019 |
March 19, 2019 |
|
- St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
Sydney, Australia - Rambam Health Care - Bone Marrow Transplantation Unit
Haifa, Israel - Hadassah Medical Center - Bone Marrow Transplantation Department, Cancer Immunotherapy and Immunobiology Research Center
Jerusalem, Israel - (and 2 more...)
|
|
| 89 |
NCT02695537 |
Active, not recruiting |
Safety, and Tolerability of Epidiolex In Patients ((Ages 1 - 19 Years) With Intractable Epilepsy |
|
|
Interventional
|
Phase 1 |
- University of Alabama at Birmingham
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate severe adverse events (increase in seizure frequency by more than 25% or any hospitalization related to increase in seizure frequency)
- Evaluate change in resting blood pressure or heart rate by 25%
- Evaluate any change in, CBC, CMP, Liver function tests (LFTSs ), Urinary Analysis or Antiepileptic drug (AED) levels considered by managing neurologists as clinically significant.
- (and 2 more...)
|
100 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02695537 |
IND# 124160 |
|
April 2015 |
February 2020 |
February 2020 |
March 1, 2016 |
November 30, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 90 |
NCT02397863 |
Available |
Epidiolex and Drug Resistant Epilepsy in Children |
|
- Drug: Cannabidiol (Epidiolex)
|
Expanded Access
|
|
- Augusta University
- State of Georgia
|
Other |
|
|
|
All |
1 Year to 18 Years (Child, Adult) |
NCT02397863 |
CBD02 |
CBD |
December 2014 |
December 2019 |
January 2020 |
March 25, 2015 |
April 24, 2015 |
|
- Georgia Regents University
Augusta, Georgia, United States
|
|
| 91 |
NCT03003260 |
Unknown † |
The Effect of CanChew® Cannabidiol (CBD) Containing Chewing Gum on Irritable Bowel Syndrome |
|
- Other: CBD chewing gum
- Other: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change of pain scores on the Visual analoge scale (VAS) between baseline and 3, 5 and 8 weeks of treatment
- Change of IBS-QOL baseline vs 3, 5 and 8 weeks of treatment
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03003260 |
NL58588.081.16 |
|
December 2016 |
April 2017 |
June 2017 |
December 26, 2016 |
December 26, 2016 |
|
- Wageningen University
Wageningen, Gelderland, Netherlands
|
|
| 92 |
NCT03825965 |
Not yet recruiting |
Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT |
|
- Drug: Cannabidiol (CBD)
- Drug: Placebo oral capsule
|
Interventional
|
Phase 3 |
- McMaster University
- St. Joseph's Healthcare Hamilton
- Hamilton Health Sciences Corporation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Persistent post-surgical pain (PPSP)
- Opioid use
- Peri-operative pain intensity
- (and 7 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03825965 |
Cannabis TKA Pilot Trial |
|
April 2019 |
April 2021 |
April 2021 |
February 1, 2019 |
March 8, 2019 |
|
- St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada - Hamilton Health Sciences - Juravinski Hospital
Hamilton, Ontario, Canada
|
|
| 93 |
NCT02607891 |
Recruiting |
A Study to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy |
|
- Drug: GWP42003-P
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Maximum plasma concentration (Cmax) of STP, VPA, cannabidiol (CBD).
- Time to the maximum plasma concentration (Tmax) of STP, VPA and CBD.
- Area under the curve (AUC) from zero to final time of positive detection (0-t) of STP, VPA and CBD.
- (and 15 more...)
|
40 |
All |
16 Years to 55 Years (Child, Adult) |
NCT02607891 |
GWEP1447 Blinded Phase
2015-002939-18 |
|
October 2016 |
August 2018 |
August 2018 |
November 18, 2015 |
November 1, 2017 |
|
- Elancourt, France
- Paris, France
- Rennes, France
- (and 7 more...)
|
|
| 94 |
NCT04045119 |
Not yet recruiting |
Effect of a Facial Cream Containing Cannabidiol and Hemp Oil on Skin Hydration and Acne-prone Skin |
|
- Other: Topical Moisturizer
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Evaluate the effect on hydration of a single application of the topical preparation on facial skin
- Evaluate the effect on hydration of periodic application of the topical preparation on facial skin
- Evaluate the short-term change in instrumentally assessed measurement of oily skin
- (and 10 more...)
|
54 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT04045119 |
Av 0002 DaCol |
Dahlia |
September 23, 2019 |
November 23, 2019 |
December 23, 2019 |
August 5, 2019 |
August 5, 2019 |
|
|
|
| 95 |
NCT02291562 |
Completed |
Effects of THC and CBD on Human Episodic Memory Function |
|
- Drug: Tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: placebo
|
Interventional
|
Not Applicable |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Changes in BOLD (blood oxygen level dependent) responses
- Changes in behavioral measures
|
20 |
Male |
18 Years to 50 Years (Adult) |
NCT02291562 |
LOGIN_EpMem |
|
July 2014 |
December 2014 |
December 2014 |
November 14, 2014 |
January 16, 2015 |
|
- Central Institute of Mental Health
Mannheim, Germany
|
|
| 96 |
NCT02700412 |
Active, not recruiting |
University of Alabama at Birmingham (UAB) Adult CBD Program |
|
|
Interventional
|
Phase 1 |
- University of Alabama at Birmingham
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate severe adverse events (increase in seizure frequency by more than 100% or any hospitalization related to increase in seizure frequency)
- Evaluate any change in resting blood pressure or heart rate by 25%
- Evaluate any change in, CBC, CMP, Liver function tests (LFTSs), Urinary Analysis or Antiepileptic drug (AED) levels considered by managing neurologists as clinically significant.
- (and 2 more...)
|
100 |
All |
15 Years to 99 Years (Child, Adult, Older Adult) |
NCT02700412 |
IND# 124138 |
|
April 2015 |
April 2021 |
April 2021 |
March 7, 2016 |
May 17, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 97 |
NCT02751359 |
Active, not recruiting |
Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- New York State Psychiatric Institute
- INSYS Therapeutics Inc
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Analgesia: Pain tolerance and threshold as measured by the Cold Pressor Test
- Subjective drug effects related to abuse liability as measured by visual analog scales
|
18 |
All |
21 Years to 50 Years (Adult) |
NCT02751359 |
7009 |
|
June 2016 |
December 2021 |
December 2021 |
April 26, 2016 |
April 3, 2019 |
|
- Cooper
New York, New York, United States
|
|
| 98 |
NCT02224560 |
Completed
Has Results |
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults |
- Epilepsy
- Lennox Gastaut Syndrome
|
- Drug: GWP42003-P
- Drug: Placebo control
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
- Number Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period
- Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
- Subject/Caregiver Global Impression Of Change (S/CGIC) Assessment
|
225 |
All |
2 Years to 55 Years (Child, Adult) |
NCT02224560 |
GWEP1414
2014-002940-42 |
GWPCARE3 |
June 8, 2015 |
May 19, 2016 |
May 19, 2016 |
August 25, 2014 |
July 27, 2018 |
July 27, 2018 |
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Los Angeles, California, United States
- (and 26 more...)
|
|
| 99 |
NCT02607904 |
Enrolling by invitation |
An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants who experienced an adverse event.
- Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).
- Number of participants with a clinically significant change in serum biochemistry.
- (and 7 more...)
|
40 |
All |
16 Years to 55 Years (Child, Adult) |
NCT02607904 |
GWEP1447 Open-label Extension
2015-002939-18 |
|
November 2016 |
August 2019 |
August 2019 |
November 18, 2015 |
November 1, 2017 |
|
|
|
| 100 |
NCT02255292 |
Unknown † |
A Study: Pure CBD as Single-agent for Solid Tumor. |
|
|
Interventional
|
Phase 2 |
- Hadassah Medical Organization
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate according to RECIST 1.1
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02255292 |
CBD- HMO-CTIL |
|
November 2014 |
July 2015 |
July 2015 |
October 2, 2014 |
October 2, 2014 |
|
|
|
Create an RSS feed from your search for:
Download the search results for: